Curasight Doses First Patient in Brain Cancer Trial

Curasight announced the successful dosing of the first patient in its Phase 1 trial of uTREAT® for brain cancer (glioblastoma). This marks the initiation of the first clinical trial for Curasight's therapeutic platform, uTREAT.